Medtronic And Boston Scientific Finance Saluda's Neuromodulation System
Executive Summary
Saluda Medical has secured funds from Medtronic and Boston Scientific to support the development of its spinal cord stimulation system for pain management.
You may also be interested in...
Saluda’s Evoke SCS Set To Join Competitive US Spine-Stim Market In Late 2022
The Australian company secured $125m in financing to support commercialization of the Evoke SCS system for chronic pain beginning in late 2022. The US FDA approved Evoke SCS for chronic intractable pain of the trunk and/or limbs, the third major FDA approval of an SCS technology this year so far.
Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
Real-World Data Support Boston Scientific’s Personalized Spinal Cord Stimulation Therapy
Results of the PRO study of Boston Scientific’s Spectra WaveWriter spinal cord stimulator support the development of “all-in-one” spinal cord stimulation technology that delivers multiple waveforms and anatomical targeting for treating low back and/or leg pain.